GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Market Cap

Rigel Pharmaceuticals (STU:RI2A) Market Cap : €153.0 Mil (As of Jun. 09, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Rigel Pharmaceuticals's share price for the quarter that ended in Mar. 2024 was €1.337. Rigel Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 175.4 Mil. Therefore, Rigel Pharmaceuticals's market cap for the quarter that ended in Mar. 2024 was €234.5 Mil.

Rigel Pharmaceuticals's quarterly market cap increased from Sep. 2023 (€181.6 Mil) to Dec. 2023 (€241.1 Mil) but then declined from Dec. 2023 (€241.1 Mil) to Mar. 2024 (€234.5 Mil).

Rigel Pharmaceuticals's annual market cap declined from Dec. 2021 (€403.3 Mil) to Dec. 2022 (€219.6 Mil) but then increased from Dec. 2022 (€219.6 Mil) to Dec. 2023 (€241.1 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rigel Pharmaceuticals's Enterprise Value for Today is €163.1 Mil.


Rigel Pharmaceuticals Market Cap Historical Data

The historical data trend for Rigel Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Market Cap Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 310.78 480.86 403.26 219.59 241.09

Rigel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 207.25 210.97 181.60 241.09 234.52

Competitive Comparison of Rigel Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Rigel Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Market Cap falls into.



Rigel Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Rigel Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=€1.379*174.826
=€241.1

Rigel Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=€1.337*175.406
=€234.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rigel Pharmaceuticals  (STU:RI2A) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Rigel Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (STU:RI2A) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines